ReviewEuropean journal of haematology2019
Pregnancy and delivery in women with von Willebrand disease.
Review in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Pooled it
- [Chinese guideline on the diagnosis and management of von Willebrand disease (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Guideline
- The clinical management of factor XI deficiency in pregnant women.Expert review of hematology · 2020Pooled it
- Acute Hemorrhagic Manifestations in a Pregnant Patient With Type 1 von Willebrand Disease: Challenges in Management of Bleeding Disorders During Gestation.Clinical case reports · 2026Article
- [Hereditary disorders of hemostasis in obstetrics 1/2-Anesthesiological aspects of primary hemostasis].Die Anaesthesiologie · 2026Review
- von Willebrand disease: an illustrated review.Research and practice in thrombosis and haemostasis · 2026Review
- Global burden and trends of depression among women of childbearing age, 1990-2021.Public health in practice (Oxford, England) · 2026Article
- Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery.Research and practice in thrombosis and haemostasis · 2026Observational
- Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease.International journal of hematology · 2026Article
- Treatment of von Willebrand disease.Blood advances · 2026Review
- Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?Therapeutic advances in hematology · 2026Review
- Von Willebrand disease: classification and epidemiology.Haematologica · 2026Review
- Gynecologic and obstetric management of girls and women with von Willebrand disease.Haematologica · 2026Review
- Pregnancy management for patients with bleeding disorders.Hematology. American Society of Hematology. Education Program · 2025Review
- Adapting haematology practices for effective management of blood disorders in pregnancy in a limited resource setting.Annals of hematology · 2025Review
- Multidisciplinary perinatal care for women with bleeding disorders.Research and practice in thrombosis and haemostasis · 2025Article
- Von Willebrand disease (VWD) and pregnancy: a comprehensive overview.Thrombosis journal · 2025Review
- Hematologic Complications of Pregnancy.European journal of haematology · 2025Review
- Von Willebrand Disease and Pregnancy: Management Protocol From Labor to the Postpartum Period.Cureus · 2024Article
- A case of delayed postoperative bleeding after excision of endometrial polyp using resectoscope in an infertile woman with von Willebrand disease:a case report and literature review.Fukushima journal of medical science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Given the wide heterogeneity of phenotypes and of the underlying pathophysiological mechanisms associated with the disorder, pregnancy and delivery in von Willebrand disease (VWD) represent a significant clinical challenge. The variable pattern of changes observed during pregnancy of von Willebrand factor (VWF) and factor VIII (FVIII), the protein carried by VWF, prompts a careful evaluation of pregnant women with VWD to plan the most appropriate treatment at the time of parturition. However, there are also instances during pregnancy (amniocentesis, vaginal bleeding associated with placental detachment, sudden abortion) that may require urgent hemostatic treatment to prevent bleeding. Thus, women with VWD should start pregnancy after being well characterised as to their type, subtype and treatments. Women with VWD who have VWF and FVIII basal levels >30 U/dL typically normalise these levels at the end of pregnancy and specific anti-haemorrhagic prophylaxis is seldom required. On the contrary, those with basal levels <20 U/dL usually show a lesser increase and specific treatment is required. Some women with DNA variants associated with increased clearance can be treated with desmopressin, while those unresponsive or with contra-indications to this agent need replacement therapy. For these latter women, the risk of vaginal bleeding during pregnancy may be increased and prophylaxis with VWF concentrates required. Similarly, women with type 2 VWD who maintain reduced VWF activity throughout pregnancy require replacement therapy with FVIII/VWF concentrates. Delayed postpartum bleeding may occur when replacement therapy is not continued for some days. Tranexamic acid is useful at discharge to avoid excessive lochia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.